Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, 100730, China.
Medical Intensive Care Unit, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, No 1. Shuaifuyuan, Dongcheng District, Beijing, 100730, China.
BMC Pulm Med. 2022 Jul 5;22(1):264. doi: 10.1186/s12890-022-02056-1.
The EmPHasis-10 questionnaire is a disease-specific quality of life (QoL) measurement in patients with pulmonary hypertension. We report the results of cross-cultural validation of the Chinese version of the EmPHasis-10 and its relationship with risk stratification in patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH).
The Emphasis-10 was administered to 75 CTD-PAH patients along with the 36-item Medical Outcomes Study Short Form Survey (SF-36) and EuroQol five dimensions questionnaire (EQ-5D). The diagnosis of PAH was confirmed by right heart catheterization. Demographic and clinical data were obtained. Multivariable logistic regression was conducted based on the low risk profile assessed by a 4-strata risk assessment model (COMPERA 2.0) at follow-up.
Date from 75 patients with CTD-PAH were analysed. The EmPHasis-10 demonstrated satisfactory reliability (Cronbach α = 0.95) and convergent validity showed by the significant relationship with WHO Functional Class (P = 0.003), SF-36 (P < 0.001) and EQ-5D (P = 0.002). EmPHasis-10 was significantly associated with achieving the low risk profile at 12 months of follow-up (Odds ratio: 0.928, P = 0.029) after adjusting for WHO Functional Class.
EmPHasis-10 has acceptable reliability and validity in CTD-PAH patients and may serve as an additional parameter in risk stratification.
EmPHasis-10 问卷是一种针对肺动脉高压患者的特定疾病生活质量（QoL）测量工具。我们报告了 EmPHasis-10 中文版本的跨文化验证结果及其与结缔组织病相关肺动脉高压（CTD-PAH）患者风险分层的关系。
对 75 例 CTD-PAH 患者进行 Emphasis-10 问卷调查，同时进行 36 项医疗结局研究短式量表（SF-36）和 EuroQol 五维问卷（EQ-5D）调查。通过右心导管检查确诊 PAH。收集人口统计学和临床数据。根据随访时的 4 层风险评估模型（COMPERA 2.0）评估低危患者，进行多变量逻辑回归分析。
分析了 75 例 CTD-PAH 患者的数据。EmPHasis-10 具有良好的可靠性（Cronbach α=0.95），与 WHO 功能分级（P=0.003）、SF-36（P<0.001）和 EQ-5D（P=0.002）均有显著相关性，表明具有良好的收敛效度。EmPHasis-10 与 12 个月时达到低危状态显著相关（OR：0.928，P=0.029），校正 WHO 功能分级后仍有统计学意义。
EmPHasis-10 在 CTD-PAH 患者中具有良好的信度和效度，可能成为风险分层的附加参数。
